There are currently 1877 clinical trials in Philadelphia, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Pennsylvania, Children's Hospital of Philadelphia, Fox Chase Cancer Center and Thomas Jefferson University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
CRS Questionnaire Validation Project
NCT06970977
Recruiting
The 'CRS validation project' consists of a joint effort of 32 medical centers in Europe, the USA, and South Africa to carry out the validation of 2 novel questionnaires designated to measure self-perceived severity and control of Chronic Rhinosinusitis (with or without nasal polyps). This study will validate translated versions of the same set of questionnaires simultaneously in the centers involved after recruiting a total of 1000 patients, while data collection, statistical analysis, and crea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Register for Updates
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
NCT05438212
Recruiting
This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation to target tumors and minimizes effect on normal surrounding brain tissue. The combination of surgery and radiation may stop the tumor from growing for a few months or longer and may reduce sy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Metastatic Malignant Neoplasm in the Brain
Register for Updates
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
NCT06613841
Recruiting
* To perform metabolic phenotyping of treatment naïve and recurrent GBM by multitracer \[18F\]Fluciclovine and 18F-FDG PET. * To compare uptake measures of 18F-Fluciclovine and 18F-FDG and MRI quantification of glutamate and lactate levels to tumor tissue laboratory assays (RNA seq and proteomics) of glutamine/glutamate, glucose, and lactate metabolism. * To perform metabolic phenotyping of treatment naïve and recurrent GBM by advanced MRI methods at 7 Tesla
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania +1 locations
Conditions: Glioblastoma, Recurrent Glioblastoma, Glioblastoma Multiforme of Brain
Register for Updates
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
05/05/2025
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Severe Aplastic Anemia
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Cardiology Consultants of Philadelphia, Philadelphia, Pennsylvania +4 locations
Conditions: Heart Failure
Register for Updates
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
NCT04127578
Recruiting
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogeni... Read More
Gender:
ALL
Ages:
Between 35 years and 80 years
Trial Updated:
05/05/2025
Locations: Hospital of the University of Pennsylvania, 330 S. 9th Street, Philadelphia, Pennsylvania
Conditions: Parkinson Disease
Register for Updates
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943
Recruiting
The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
05/05/2025
Locations: CHOP Abramson Pediatric Resch Ctr, Philadelphia, Pennsylvania
Conditions: Lymphatic Malformations
Register for Updates
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
NCT05722938
Recruiting
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Jefferson University Hospitals, Philadelphia, Pennsylvania
Conditions: Community-acquired Pneumonia
Register for Updates
Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia
NCT06968663
Recruiting
The goal of this clinical trial is to determine if Transcranial Magnetic Stimulation (TMS) combined with modified Constraint Induced Language Therapy (mCILT) is an effective treatment for aphasia when delivered in the subacute stage after stroke. The main questions this study aims to answer are: 1. Can TMS combined with mCILT improve overall speech? 2. Can we identify specific behavioral and biological characteristics that would benefit most from the TMS and mCILT treatment? Researchers will... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/05/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Stroke, Aphasia, Aphasia Following Cerebral Infarction
Register for Updates
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
NCT04064827
Recruiting
The main objective of this study is to evaluate the safety, efficacy and pharmacokinetics of paricalcitol oral solution in pediatric participants of ages 0 to 9 years with SHPT associated with stage 5 CKD receiving Peritoneal Dialysis (PD) or Hemodialysis (HD). The 24-week study is divided into two 12-week dosing periods (Dosing Period 1 followed by Dosing Period 2).
Gender:
ALL
Ages:
Between 0 years and 9 years
Trial Updated:
05/05/2025
Locations: Children's Hospital of Philadelphia - Main /ID# 213802, Philadelphia, Pennsylvania
Conditions: Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Register for Updates
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116
Recruiting
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/05/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Diagnosis
NCT06652568
Recruiting
The purpose of this study is to confirm the safety and efficacy of the ThinkSono Guidance System, a software data collection and communication tool designed to collect ultrasound data to help detect blood clots in veins. The ThinkSono system is CE Mark approved in the European Union and in clinical use in Europe. Usually, when an ultrasound is conducted to diagnose blood clots in veins, a sonographer (trained technologist who conducts ultrasounds) and/or radiologist will conduct the procedure, i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2025
Locations: Temple Health, Philadelphia, Pennsylvania
Conditions: Deep Vein Thrombosis, Deep Vein Thrombosis, Pulmonary Embolus
Register for Updates